Alzheimer’s Association International Conference 2026 (AAIC 2026)

London, UK 12 July 2026 - 16 July 2026

Lecanemab sustains benefit for AD in 3-year LEADER update

04 Sep 2026 by

Three years post-initial US FDA approval, lecanemab still shows ongoing clinical benefits and reduces amyloid plaques in patients with early Alzheimer’s disease (AD).

Lecanemab sustains benefit for AD in 3-year LEADER update

04 Sep 2026

Donanemab shows long-term benefits in early symptomatic AD

29 Aug 2026 by

Treatment with donanemab continues to show increasing clinical benefits in patients with early symptomatic Alzheimer’s disease (AD), according to the phase III TRAILBLAZER‐ALZ 2 long-term extension (LTE) study presented at AAIC 2026.

Donanemab shows long-term benefits in early symptomatic AD

29 Aug 2026

Multidomain lifestyle intervention improves cognition among older adults at high risk of dementia

27 Aug 2026 by

A multidomain, systematic lifestyle intervention (SLI) may yield a significantly greater improvement in global cognitive function over 2 years compared with a flexible lifestyle intervention (FLI) among older adults at high risk of dementia, according to the LatAm-FINGERS* trial presented at AAIC 2026.

Multidomain lifestyle intervention improves cognition among older adults at high risk of dementia

27 Aug 2026

Tau-targeting therapy for early AD gets a pass to phase III

07 Aug 2026 by

In the phase II CELIA trial, the investigational tau-targeting antisense oligonucleotide (ASO) diranersen has shown therapeutic potential in patients with early Alzheimer’s disease (AD), yielding substantial reductions in tau burden and slowing clinical decline despite missing its primary endpoint.

Tau-targeting therapy for early AD gets a pass to phase III

07 Aug 2026

High outdoor heat detrimental to individuals with dementia

07 Aug 2026 by

A study presented at AAIC 2026 shows that short-term exposure to outdoor heat may exacerbate behavioural and psychological symptoms of dementia (BPSD), including affective and psychotic manifestations.

High outdoor heat detrimental to individuals with dementia

07 Aug 2026

Cannabinoid combination quells agitation in late-stage dementia patients

05 Aug 2026 by

The experimental combination of tetrahydrocannabinol (THC) plus cannabidiol (CBD) proves beneficial in reducing agitation in hospice care-eligible patients with late-stage dementia, according to the phase II LiBBY trial.

Cannabinoid combination quells agitation in late-stage dementia patients

05 Aug 2026

Elevated p-tau217 levels may help identify dementia risk early

03 Aug 2026 by

A pooled analysis presented at AAIC^® 2026 demonstrated a consistent association between higher levels of plasma phosphorylated tau 217 (p-tau217) and an increased risk of clinical progression and accelerated cognitive decline in a large cohort of older adults without cognitive impairment.

Elevated p-tau217 levels may help identify dementia risk early

03 Aug 2026

GLP-1RA exposure lowers mortality in patients with dementia

25 Jul 2026 by

The use of glucagon-like peptide-1 receptor agonist (GLP-1RA) appears to prevent all-cause deaths among patients with dementia, as shown in a retrospective cohort study presented at AAIC 2026.

GLP-1RA exposure lowers mortality in patients with dementia

25 Jul 2026

Blood test enables physicians to rule out Alzheimer’s disease in primary care

24 Jul 2026 by

A blood-based biomarker (BBM) test for Alzheimer’s disease (AD) allows primary care physicians to diagnose AD with the same precision as specialists, suggests a study presented at AAIC 2026.

Blood test enables physicians to rule out Alzheimer’s disease in primary care

24 Jul 2026